Navigation Links
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Date:5/21/2008

ic to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REB
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
4. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
5. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
6. Schering-Plough Reports Top-Line Results of the IDEAL Study
7. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
8. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
9. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
10. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
11. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... in the Tel Aviv area ... promote WuXi,s broad platform of integrated R&D services to ...
(Date:10/30/2014)... -- The number of retail health clinics in ... to drug store chains, according to Kalorama Information.  In ... retail clinic growth had been at a standstill, but ... of retail clinics reached nearly 1,600 according to the ... and 2014 Consumer Survey Results .  More ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Genmab A/S (CSE: GEN),announced today that the results ... patients with rheumatoid,arthritis (RA) have been accepted for ... Rheumatology (EULAR). The oral,presentation, which will include new ... with ofatumumab, along with data,from the previous interim ...
... Study Shows At Least 10 Genetic Variants Are ... 26, 2007 – In the most,comprehensive look at ... a U.S.-Finnish team, working in close collaboration with ... genetic variants,associated with increased risk of diabetes and ...
Cached Medicine Technology:Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 2Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 3Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 4Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 5Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 6Researchers Identify New Genetic Risk Factors for Type 2 Diabetes 7
(Date:10/30/2014)... Don Allred Insurance, a leading provider of ... North Carolina residents, is excited to announce the Grand ... Mall. The new branch has been up and running ... all facets of the insurance selection process from quote ... Allred couldn’t be happier with the timing of this ...
(Date:10/30/2014)... Five months after their expansion, the ... announces new branding and a website to accompany their ... David Mepham’s promotion to name partner earlier this year, ... include Mepham’s name and better reflect their combined litigation ... the decision to implement new branding reflects Hodgkinson Street ...
(Date:10/30/2014)... 2014 Paramount Rx, a full-service prescription ... efforts to help people save money through its innovative ... for prescription drugs in the new health care system, ... to bridge the relationship between consumers, businesses and the ... challenges people face today with medical costs is the ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... with prostate cancer who also have certain heart problems may ... new study suggests. , , The therapy in question is called ... reduce levels of male hormones to prevent the growth of ... research, this hormone therapy was linked to triple the risk ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... Ebola outbreak in Liberia -- one of three West African ... Health Organization officials said Wednesday. Dr. Bruce Aylward, WHO,s ... number of burials in Liberia and no increase in laboratory-confirmed ... push to tame the epidemic may be making some progress, ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... better known for their close association to fishes has ... ,Dietary intake of omega 3 fatty acids such ... may curb the growth of breast cancer cells, ... of Cancer., ,Min Wu and colleagues at Methodist ...
... study in USA to see if the procedures of ... ,The study will enroll of more than 16,000 ... be safely performed in smaller, community hospitals, easing access ... the first study patients in early fall 2005. ...
... cancer remain the most feared diseases all around the ... inhaler, potentially offering adult diabetics an alternative to injections// ... to be approved by the FDA. ,If approved, ... to the insulin injections taken by millions worldwide. The ...
... people may accelerate the heart conditions by releasing the levels ... of 32 people with heart failure, the 14 patients who ... this protein in their blood. ,The protein, tumor necrosis ... of proteins called cytokines, chemical messengers that are mobilized when ...
... Research suggests that 25% of the MRSA infections in the ... the hospital. The research was published in the latest ... many sites; one serious form of infection is that in ... scheme counts MRSA bacteremia by hospital trust, but it has ...
... doctors of American Origin are helping out the victims from ... members of the American Association of Physicians of Indian Origin// ... US who number over 25,000 - have volunteered their services ... Mississippi and Alabama. ,The volunteers hail from almost all ...
Cached Medicine News:Health News:Exubera could mean the end of an insulin injection era for diabetics 2Health News:Indian doctors in America help Katrina victims 2
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Fujinon's standard fiberoptic bronchoscope is fully submersible and offers a large image for more comfortable and efficient observation....
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
... The BF-1T40 has been designed with a ... in therapeutic applications. This permits the selection ... those for electrosurgical procedures. In addition, this ... field of view and a bright, high-resolution ...
Medicine Products: